Citations

Clear

18 citation(s) found for "Cohen, Stacey A".

Addition of High-Dose Vitamin D 3 to Standard Treatment in Patients With Metastatic Colorectal Cancer
Ng, Kimmie, Zemla, Tyler, Jackson, Nadine, Kalyan, Aparna, Devoe, Craig, Shusterman, Michael , Vijayvergia, Namrata , Wu, Christina S., Cohen, Stacey A., Pulsipher, Sidney, Shergill, Ardaman, Watson, Yasmeem, Kleiber, Barbara , Lee, Myounghee, Kohn, Christine G. , Zuckerman, Dan, Hollis, Bruce W., O’Reilly, Eileen M., Meyerhardt, Jeffrey A., Pulsipher, Sydney , Ng, Kimmie , Ou, Fang‐Shu , Zemla, Tyler , Devoe, Craig , Cohen, Stacey A. , Thalappillil, Jennifer S. , Schwartz, Lawrence H. , Zuckerman, Dan, Hollis, Bruce W. , O’Reilly, Eileen M. , Meyerhardt, Jeffrey A.

Mayo Clinic

JAMA | August 3, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1001/jama.2026.9350 | PMID 42545685 Get It

Importance In a phase 2 randomized clinical trial, high-dose vitamin D 3 added to standard treatment improved progression-free survival (PFS) compared with standard-dose vitamin D 3 in patients with metastatic colorectal cancer (mCRC). Objective To determine if high-dose vitamin D 3 added to standard chemotherapy improves outcomes in patients with previously untreated mCRC. Design, Setting, and Participants Double-blind phase 3 randomized clinical trial enrolling 455 patients with previously untreated mCRC, conducted in the US through the National Clinical Trials Network from October 2019 to December 2022 (database freeze: July 15, 2024). Interventions mFOLFOX6 (modified FOLFOX6 [5-fluorouracil, leucovorin, oxaliplatin]) or FOLFIRI (5-fluorouracil, leucovorin, irinotecan) plus bevacizumab every 2 weeks with either high-dose vitamin D 3 (8000 IU daily × 14 days as loading dose followed by 4000 IU daily) or standard-dose vitamin D 3 (400 IU daily) until disease progression, intolerable toxicity, or withdrawal of consent. Main Outcomes and Measures The primary end point was PFS assessed by the unstratified log-rank test. Secondary end points included objective response rate, overall survival, and toxicity. Prespecified subgroup analyses of PFS were performed according to known prognostic factors. Results Among 455 randomized patients (median age, 59 years; 181 [40%] female) with median follow-up 20 months, the median PFS for high-dose vitamin D 3 (n = 228) was 11.8 months (95% CI, 10.3-13.3) vs 10.3 months (95% CI, 9.4-12.2) for standard-dose vitamin D 3 (n = 227) (1-sided log-rank P = .25). There were no significant differences in objective response rate between high-dose and standard-dose vitamin D 3 (51% [95% CI, 44%-58%] vs 44% [95% CI, 37%-50%], respectively; P = .12), or in overall survival (median, 25.6 vs 27.0 months; 1-sided log-rank P = .66). There were no clinically meaningful differences in the most common grade 3 or greater adverse events between the high- and standard-dose groups, including neutropenia (n = 67 [32%] vs n = 62 [30%]) and hypertension (n = 42 [20%] vs n = 49 [23%]) or in incidence of vitamin D–associated toxicities. Conclusions and Relevance Among patients with previously untreated mCRC, addition of high-dose vitamin D 3 , vs standard-dose vitamin D 3 , to standard chemotherapy plus bevacizumab did not improve PFS. Trial Registration ClinicalTrials.gov Identifier: NCT04094688
Gene Portals: A Framework for Integrating Clinical, Functional, and Structural Evidence into Rare Disease Variant Classification
Brünger, Tobias , Krey, Ilona , Kim, Suyeon, Klöckner, Chiara , Myers, Scott J, Johannesen, Katrine M. , Stefanski, Arthur , Taylor, Gary, Macnee, Marie , Dahl, Rebekka S., Yuan, Hongjie, Kim, Sukhan, Helbig, Ingo, Pan, Jen, Kurganov, Erkin , Baez, David, Zuberi, Sameer M., Lerche, Holger, May, Patrick, Ivaniuk, Alina, Meskis, Mary Anne , Hood, Veronica , Schust, Leah F., Freed, Amber, Froelich, Steven, Deng, Alexander T., Bouman, Arjan , Hajianpour, M.J. , Pal, Deb K. , Danvoye, Leslie, Lederer, Damien , BALCI, TUĞÇE, Hagebeuk, Eveline , Heidlebaugh, Alexis R. , Oetjens, Kathryn F., Striano, Pasquale, Williams, Sarah Drewes, Engelen, Kalene van , Howell, Katherine B. , Khoury, Jean , Benke, Tim A., Strehlow, Vincent , Platzer, Konrad, Ramsey, Amy J, Manaster, Lisa, Malepati, Sunitha, Fox, Pangkong M., Noebels, Jeffrey, Chung, Wendy, Poduri, Annapurna, Stripe, Laina Lusk, Ruggiero, Sarah M., Cohen, Stacey, Wilmarth, Olivia, Prentice, Anna Jenne, Cha, Esther, Budnik, Nikita , Kramer, Audra A. , Gh, Zhang, Palotie, Aarno, Daly, Mark J., Møller, R., Lemke, Johannes R., Lal, Dennis , Møller, Rikke S. , May, Patrick , Bruenger, Tobias , Pan, Jen Q , Farrant, Mark , Wyllie, David J A , Bosselmann, Christian , Mantegazza, Massimo , May, Patrick , Ivaniuk, Alina , Goodspeed, Kimberly , Trinidad, Marena , Aledo-Serrano, Ángel , Pal, Deb K , Platzer, Konrad , Ruggiero, Sarah M , Daly, Mark J. , George, Alfred L , Brunklaus, Andreas , Møller, Rikke S , Myers, Scott J. , Taylor, Gary, Pérez‐Palma, Eduardo , Schorge, Stéphanie , Dahl, Rebekka S. , Perszyk, Riley E. , Bajaj, Sunanjay , Helbig, Ingo , Wollmuth, Lonnie P. , Báez-Nieto, David , Zuberi, Sameer M. , Boßelmann, Christian M. , Mantegazza, Massimo , Cestèle, Sandrine , Ivaniuk, Alina , Kang, Jing‐Qiong , Gati, Cornelius , Montanucci, Ludovica , Wüster, Arthur , Deng, Alexander T. , Borovikov, Artem O. , Sharkov, Artem A. , Bouman, Arjan , Hoffman, Trevor L. , Howell, Katherine B. , Benke, Tim A. , Platzer, Konrad , Ramsey, Amy J. , Fox, Pangkong , Noebels, Jeffrey L. , Chung, Wendy K. , Poduri, Annapurna , Lusk, Laina G. , Cohen, Stacey , Smith, Lacey A. , Boesch, Sylvia , Prentice, Anna Jenne , Hommersom, Marina P. , Vanoye, Carlos G. , Nothnagel, Michael , Palotie, Aarno V. , George, Alfred L. , Zárate, Yuri A. , Brunklaus, Andreas , Traynelis, Stephen F. , Lemke, Johannes R.

Mayo Clinic

No container title available | March 6, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.64898/2026.03.05.26347086 | PMID 41822692 Get It

Abstract Rare Mendelian disorders affect 300-400 million people globally. Although genetic testing has become widely adopted, gene-specific evidence for tailored variant interpretation remains scattered across resources. We present Gene Portals, a framework for gene-centered multimodal knowledge bases that co-localize expert-harmonized clinical data, functional assays, population variation, structural annotations and gene-specific ACMG/AMP specifications within a single resource. A modular interface integrates this unified evidence with VCEP-refined ACMG specifications to enable automated gene-specific variant classification, infer molecular mechanisms, and support cross-gene analyses. We demonstrate the framework’s utility across five Gene portals spanning eleven neurodevelopmental disorder-associated genes, integrating data from 4,423 individuals with 2,838 unique variants, 36,149 ClinVar submissions, and 1,044 expert-curated molecular readouts. By organizing evidence that is otherwise dispersed across multiple sources into a unified, queryable framework, the SCN, GRIN, CACNA1A, SATB2 and SLC6A1 Gene Portals became widely used community resources and provide an extensible template for standardized rare-disease variant interpretation and mechanism-aware discovery.
Real-world Monitoring of ctDNA Reliably Predicts Cancer Recurrence and Treatment Efficacy in Patients with Resected Stages I-III Colon Cancer
Cohen, Stacey A. , Aushev, Vasily N. , Nagarajan, Arun , Wang, Chongkai , Alyunis, Fadhel, Tejani, Mohamedtaki Abdulaziz, Alqahtani, Ali , Marshall, John C., Chang, Jeremy , Manage, Kevin, George, Giby V., Malhotra, Meenakshi , Chandana, Sreenivasa R , Mehler, Shoshana , Somer, Bradley G. , Babadi, Ellie, Hanna, Diana L. , Chidharla, Anusha , Kasi, Anup , Vosoughi, Elham , Briski, Robert , Azzi, Georges, Katiyar, Vatsala , Sharma, Vivek R. , Shreenivas, Aditya , Fuqua, Jacob , Malla, Midhun , Polite, Blasé N. , Bent, Alisha H., Liu, Minetta C. , Aleshin, Alexey , Cohen, Stacey A , Laliotis, George , Jabbal, Iktej Singh , Fakih, Marwan , Sharif, Saima , Botta, Gregory P. , George, Giby V., Sharma, Shruti , Wu, Christina N. , Dayyani, Farshid , Pedersen, Katrina S. , Chan, Abigail Sy , Chakrabarti, Sakti , Bent, Alisha , Rabinowitz, Matthew , Jurdi, Adham Adel , Kopetz, Scott

Mayo Clinic

Annals of Surgery | August 7, 2025 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1097/sla.0000000000006887 | PMID 40772634 Get It

Objective: In this study, we evaluate the utility of ctDNA analysis in a large cohort of patients for whom ctDNA testing was ordered commercially with real-world application. Summary Background Data: Circulating tumor DNA (ctDNA) has emerged as a prognostic and predictive biomarker for assessing post-surgical molecular residual disease (MRD) and response to treatment. Methods: A real-world data analysis was performed using commercial ctDNA testing (SignateraTM) from patients (N=795, n=5,971 plasma samples) with stage I-III colon cancer treated at multiple US institutions. The association of ctDNA detection within the MRD window, during surveillance, and the impact of ACT was correlated with patient outcomes. Results: ctDNA-positive patients during the MRD window and surveillance showed significantly shorter DFS compared to ctDNA-negative patients (hazard ratio (HR): 9.85, P<0.0001; HR: 26.91, P<0.0001). Multivariate analysis of the MRD window revealed ctDNA-positivity as the most significant factor associated with inferior DFS (adjHR: 7.7, P<0.001). MRD-positive patients who received ACT showed improved DFS compared to patients observed post-surgery (adjHR: 6.1, FDR adj P=0.0007). No ACT benefit was observed in MRD-negative patients (adj HR: 1.20, FDR adj P=0.768). On evaluating ctDNA dynamics from MRD to surveillance, patients who remained ctDNA-positive or converted from negative to positive showed a significantly inferior DFS (HR: 34.40, P<0.0001; HR: 13.65, P<0.0001) compared to persistently ctDNA-negative patients. Conclusions: Postsurgical ctDNA detection is prognostic of relapse and potentially predictive of ACT benefit in patients with resectable colon cancer, which may enable personalized surveillance, intervention, and/or trial options, ultimately improving patient outcomes.
Conserved missense variant pathogenicity and correlated phenotypes across paralogous genes
Bruenger, Tobias , Ivanuk, Alina, Cohen, Stacey , May, Patrick , Lal, Dennis , May, Patrick , Brünger, Tobias , Pérez‐Palma, Eduardo , Montanucci, Ludovica , Smith, Lacey A. , Parthasarathy, Shridhar , Helbig, Ingo , Nothnagel, Michael

Mayo Clinic

No container title available | November 29, 2024 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-5434140/v1 Get It

Abstract Background The majority of missense variants in clinical genetic tests are classified as variants of uncertain significance. Prior research has shown that the deleterious effects and the subsequent molecular consequence of variants are often conserved among paralogous protein sequences within a gene family. Here, we systematically quantified on an exome-wide scale if the existence of pathogenic variants in paralogous genes at a conserved position could serve as evidence for the pathogenicity of a new variant. For the gene family of voltage-gated sodium channels where variants and expert-curated clinical phenotypes were available, we also assessed whether phenotype patterns of multiple disorders for each gene were also conserved across variant positions within the gene family. Methods We developed a framework that assesses the presence of pathogenic missense variants located in conserved residues across paralogous genes. We systematically mapped 2.5 million pathogenic and general population variants from the ClinVar, HGMD, and gnomAD databases onto a total of 9,990 genes and aligned them by gene families. We evaluated the quantity of classifiable amino acids by utilizing pathogenic variants identified in databases alone and then compared this assessment to the inclusion of paralogous pathogenic variants. We validated and quantified the evidence of conserved pathogenic paralogous variants in variant pathogenicity classification. Results Considering conserved pathogenic variants in paralogous genes, increased the number of classifiable variants 2.8-fold across the exome, compared to pathogenic variants in the gene of interest alone. The presence of a pathogenic variant in a paralogous gene is associated with a positive likelihood ratio of 8.32 for variant pathogenicity. The likelihood ratio was gene family-specific. Across ten genes encoding voltage-gated sodium channels and 22 expert-curated disorders, we identified cross-paralog correlated phenotypes based on 3D structure spatial position. For example, the established loss-of-function disorders SCN1A-associated Dravet syndrome, SCN2A-associated autism, SCN5A-associated Brugarda Syndrome, and SCN8A-associated neurodevelopmental disorder without seizures were correlated in their spatial variant position on structure. Finally, we show that phenotype integration in paralog variant selection improves variant classification. Conclusion Our results show that paralogous variants, in particular with phenotype information can enhance our understanding of variant effects.
NCCN Guidelines® Insights: Rectal Cancer, Version 3.2024
Benson, Al B. , Adam, Mohamed A. , Chang, George J. , Chen, Yi-Jen, Cooper, Harry S. , Deming, Dustin A. , Garrido‐Laguna, Ignacio , Grem, Jean L. , Haste, Paul, Hecht, J. Randolph, Hoffe, Sarah E. , Hunt, Steven R., Johung, Kimberly L. , Joseph, Nora, Kirilcuk, Natalie, Krishnamurthi, Smitha , Malla, Midhun , Maratt, Jennifer K. , Messersmith, Wells A. , Meyerhardt, Jeffrey A. , Mulcahy, Mary F. , Nurkin, Steven, Parikh, Aparna, Patel, Hitendra , Shibata, David , Shogan, Benjamin D. , Skibber, John M., Sofocleous, Constantinos T. , Tavakkoli, Anna , Willett, Christopher G. , Wu, Christina, Jones, Frankie, Gurski, Lisa A., Meyerhardt, Jeffrey A , Venook, Alan P. , Chen, Yi‐Jen , Ciombor, Kristen K. , Cohen, Stacey A. , Hussan, Hisham , Miller, Eric D. , Patel, Hitendra, Pedersen, Katrina S. , Saltz, Leonard B. , Schneider, Charles John

Mayo Clinic

Journal of the National Comprehensive Cancer Network | August 16, 2024 | Volume: 22 | Issue: 6 | Pages: 366-375

10.6004/jnccn.2024.0041 | PMID 39151454 Get It

The determination of an optimal treatment plan for an individual patient with rectal cancer is a complex process. In addition to decisions relating to the intent of rectal cancer surgery (ie, curative or palliative), consideration must also be given to the likely functional results of treatment, including the probability of maintaining or restoring normal bowel function/anal continence and preserving genitourinary functions. Particularly for patients with distal rectal cancer, finding a balance between curative-intent therapy while having minimal impact on quality of life can be challenging. Furthermore, the risk of pelvic recurrence is higher in patients with rectal cancer compared with those with colon cancer, and locally recurrent rectal cancer is associated with a poor prognosis. Careful patient selection and the use of sequenced multimodality therapy following a multidisciplinary approach is recommended. These NCCN Guidelines Insights detail recent updates to the NCCN Guidelines for Rectal Cancer, including the addition of endoscopic submucosal dissection as an option for early-stage rectal cancer, updates to the total neoadjuvant therapy approach based on the results of recent clinical trials, and the addition of a “watch-and-wait” nonoperative management approach for clinical complete responders to neoadjuvant therapy.
Colon Cancer, Version 3.2024, NCCN Clinical Practice Guidelines in Oncology
Benson, Al B. , Adam, Mohamed A. , Chang, George J. , Chen, Yi-Jen, Cooper, Harry S. , Deming, Dustin A. , Garrido‐Laguna, Ignacio , Grem, Jean L. , Haste, Paul, Hecht, J. Randolph, Hoffe, Sarah E. , Hunt, Steven R., Johung, Kimberly L. , Joseph, Nora, Kirilcuk, Natalie, Krishnamurthi, Smitha , Malla, Midhun , Maratt, Jennifer K. , Messersmith, Wells A. , Meyerhardt, Jeffrey A. , Mulcahy, Mary F. , Nurkin, Steven, Overman, Michael J. , Parikh, Aparna, Patel, Hitendra , Shibata, David , Shogan, Benjamin D. , Skibber, John M., Sofocleous, Constantinos T. , Tavakkoli, Anna , Willett, Christopher G. , Wu, Christina, Gurski, Lisa A., Snedeker, Jenna, Jones, Frankie, Meyerhardt, Jeffrey A , Venook, Alan P. , Chen, Yi‐Jen , Ciombor, Kristen K. , Cohen, Stacey A. , Hussan, Hisham , Miller, Eric D. , Patel, Hitendra, Pedersen, Katrina S. , Saltz, Leonard B. , Schneider, Charles John

Mayo Clinic

Journal of the National Comprehensive Cancer Network | June 11, 2024 | Volume: 22 | Issue: 2D | Pages: No page available

10.6004/jnccn.2024.0029 | PMID 38862008 Get It

Colorectal cancer (CRC) is the fourth most frequently diagnosed cancer and the second leading cause of cancer death in the United States. Management of disseminated metastatic CRC involves various active drugs, either in combination or as single agents. The choice of therapy is based on consideration of the goals of therapy, the type and timing of prior therapy, the mutational profile of the tumor, and the differing toxicity profiles of the constituent drugs. This manuscript summarizes the data supporting the systemic therapy options recommended for metastatic CRC in the NCCN Guidelines for Colon Cancer.
Evaluating the utility of ZNF331 promoter methylation as a prognostic and predictive marker in stage III colon cancer: results from CALGB 89803 (Alliance)
Nakasone, Elizabeth S. , Lin, She Yu, Innocenti, Federico , Cohen, Stacey A. , Zemla, Tyler J, Cohen, Stacey A , Zemla, Tyler , Yu, Ming , Ou, Fang‐Shu , Carter, Kelly , Saltz, Leonard B. , Grady, William M.

Mayo Clinic

Epigenetics | May 8, 2024 | Volume: 19 | Issue: 1 | Pages: No page available

10.1080/15592294.2024.2349980 | PMID 38716804 Get It

Anal Carcinoma, Version 2.2023, NCCN Clinical Practice Guidelines in Oncology
Benson, Al B. , Al-Hawary, Mahmoud M. , Azad, Nilofer, Chen, Yi‐Jen , Cooper, Harry S. , Deming, Dustin A. , Garrido‐Laguna, Ignacio , Grem, Jean L. , Hecht, J. Randolph, Hoffe, Sarah E. , Hunt, Steven R., Johung, Kimberly L. , Joseph, Nora, Kirilcuk, Natalie, Krishnamurthi, Smitha , Maratt, Jennifer K. , Messersmith, Wells A. , Meyerhardt, Jeffrey A. , Mulcahy, Mary F. , Nurkin, Steven, Overman, Michael J. , Patel, Hitendra , Shibata, David , Skibber, John M., Sofocleous, Constantinos T. , Stotsky‐Himelfarb, Eden, Tavakkoli, Anna , Willett, Christopher G. , Algieri, Frankie, Gurski, Lisa A., Stehman, Katie, Meyerhardt, Jeffrey A , Venook, Alan P. , Ciombor, Kristen K. , Cohen, Stacey A. , Hubbard, Joleen M. , Hussan, Hisham , Jeck, William R. , Miller, Eric D. , Parikh, Aparna R. , Patel, Hitendra, Pedersen, Katrina S. , Saltz, Leonard B. , Schneider, Charles John , Williams, Grant R.

Mayo Clinic

Journal of the National Comprehensive Cancer Network | June 12, 2023 | Volume: 21 | Issue: 6 | Pages: 653-677

10.6004/jnccn.2023.0030 | PMID 37308125 Get It

This discussion summarizes the NCCN Clinical Practice Guidelines for managing squamous cell anal carcinoma, which represents the most common histologic form of the disease. A multidisciplinary approach including physicians from gastroenterology, medical oncology, surgical oncology, radiation oncology, and radiology is necessary. Primary treatment of perianal cancer and anal canal cancer are similar and include chemoradiation in most cases. Follow-up clinical evaluations are recommended for all patients with anal carcinoma because additional curative-intent treatment is possible. Biopsy-proven evidence of locally recurrent or persistent disease after primary treatment may require surgical treatment. Systemic therapy is generally recommended for extrapelvic metastatic disease. Recent updates to the NCCN Guidelines for Anal Carcinoma include staging classification updates based on the 9th edition of the AJCC Staging System and updates to the systemic therapy recommendations based on new data that better define optimal treatment of patients with metastatic anal carcinoma.
Rectal Cancer, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology
Benson, Al B. , Al-Hawary, Mahmoud M. , Azad, Nilofer, Chen, Yi‐Jen , Cooper, Harry S. , Deming, Dustin A. , Garrido‐Laguna, Ignacio , Grem, Jean L. , Hecht, J. Randolph, Hoffe, Sarah E. , Hunt, Steven R., Johung, Kimberly L. , Kirilcuk, Natalie, Krishnamurthi, Smitha , Maratt, Jennifer K. , Messersmith, Wells A. , Meyerhardt, Jeffrey A. , Mulcahy, Mary F. , Nurkin, Steven, Overman, Michael J. , Parikh, Aparna, Patel, Hitendra , Shibata, David , Skibber, John M., Sofocleous, Constantinos T. , Stotsky‐Himelfarb, Eden, Tavakkoli, Anna , Willett, Christopher G. , Gregory, Kristina M., Gurski, Lisa A., Meyerhardt, Jeffrey A , Venook, Alan P. , Ciombor, Kristen K. , Cohen, Stacey A. , Gunn, Andrew, Hubbard, Joleen M. , Jeck, William R. , Miller, Eric D. , Patel, Hitendra, Pedersen, Katrina S. , Saltz, Leonard B. , Schneider, Charles John

Mayo Clinic

Journal of the National Comprehensive Cancer Network | October 14, 2022 | Volume: 20 | Issue: 10 | Pages: 1139-1167

10.6004/jnccn.2022.0051 | PMID 36240850 Get It

This selection from the NCCN Guidelines for Rectal Cancer focuses on management of malignant polyps and resectable nonmetastatic rectal cancer because important updates have been made to these guidelines. These recent updates include redrawing the algorithms for stage II and III disease to reflect new data supporting the increasingly prominent role of total neoadjuvant therapy, expanded recommendations for short-course radiation therapy techniques, and new recommendations for a “watch-and-wait” nonoperative management technique for patients with cancer that shows a complete response to neoadjuvant therapy. The complete version of the NCCN Guidelines for Rectal Cancer, available online at NCCN.org , covers additional topics including risk assessment, pathology and staging, management of metastatic disease, posttreatment surveillance, treatment of recurrent disease, and survivorship.
Evaluation of methylated DCR1 as a biomarker for response to adjuvant irinotecan-based therapy in stage III colon cancer: cancer and leukaemia Group B 89803 (Alliance)
Symonds, Lynn , Carter, Kelly , Innocenti, Federico , Bosch, Linda J.W. , Meijer, Gerrit A , Carvalho, Beatriz , Zemla, Tyler J, Carter, Kelly , Meijer, Gerrit A , Yu, Ming , Zhang, Yuhong , Ou, Fang‐Shu , Zemla, Tyler , Bertagnolli, Monica M. , Grady, William M. , Cohen, Stacey A.

Mayo Clinic

Epigenetics | April 12, 2022 | Volume: 17 | Issue: 12 | Pages: 1715-1725

10.1080/15592294.2022.2058225 | PMID 35412430 Get It